  Objective: To conduct a meta-analysis of current studies that examined sex
differences in severity and mortality in patients with COVID-19, and identify
potential mechanisms underpinning these differences. Methods: We performed a
systematic review to collate data from observational studies examining
associations of sex differences with clinical outcomes of COVID-19. PubMed, Web
of Science and four preprint servers were searched for relevant studies. Data
were extracted and analyzed using meta-analysis where possible, with summary
data presented otherwise. Publicly available bulk RNA sequencing (RNA-seq),
single-cell RNA sequencing (scRNA-seq), and chromatin immunoprecipitation
sequencing (ChIP-seq) data were analyzed to explore the potential mechanisms
underlying the observed association. Results: 39 studies met inclusion
criteria, representing 77932 patients, of which 41510 (53.3%) were males. Men
were at a markedly increased risk of developing severe cases compared with
women. Furthermore, the pooled odds ratio (OR) of mortality for male group
compared with the female group indicated significant higher mortality rate for
male. Data from scRNA-seq suggest that men have a higher amount of
ACE2-expressing pulmonary alveolar type II cells than women. Sex-based
immunological differences exist. The expression of androgen receptor (AR) is
positively correlated with ACE2, and there is evidence that AR may directly
regulate the expression of ACE2. Conclusions: This meta-analysis detected an
increased severity and mortality rate in the male populations with COVID-19,
which might be attributable to the sex-based differences in cellular
compositions and immunological microenvironments of the lung. The host cell
receptor ACE2 is likely regulated by AR signaling pathway, which is identified
as a potential target for prevention and treatment of SARS-Cov-2 infections in
men.
